Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

September 7, 2021

Primary Completion Date

February 27, 2023

Study Completion Date

January 31, 2026

Conditions
C3GIC-MPGNRenal TransplantComplement 3 GlomerulopathyComplement 3 Glomerulopathy (C3G)Dense Deposit Disease (DDD)Membranoproliferative GlomerulonephritisMembranoproliferative Glomerulonephritis (MPGN)Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)C3 GlomerulopathyC3 GlomerulonephritisComplement 3 Glomerulonephritis
Interventions
DRUG

Pegcetacoplan

Complement (C3) Inhibitor

Trial Locations (25)

1005

CHUV, Lausanne

1090

Medical University of Vienna, Vienna

3050

The Royal Melbourne Hospital, Parkville

3168

Monash Medical Centre, Clayton

10016

NYU Langone Health Transplant Insitute, New York

10032

CUIMC, New York

24020

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Ranica

28041

Hospital Universitario 12 de Octubre, Nephrology Department, Madrid

55905

Mayo Clinic, Rochester

59000

Lille Regional University Hospital Center, Claude Huriez Hospital, Department of Nephrology, Lille

63110

Washington University, St.Louis, St Louis

69437

Hopital Edouard Herriot, Hospices Civils de Lyon, Lyon

80045

Children's Hospital Colorado, Aurora

85054

Mayo Clinic Arizona, Phoenix

900033

Keck School of Medicine, University of Southern California, Los Angeles

B1888AAE

Hospital de Alta Complejidad en Red El Cruce Dr. Nestor Carlos Kirchner, San Juan Bautista

C1093AAS

Hospital Universitario Fundacion Favaloro, Buenos Aires

90020-090

Irmandade da Santa Casa de Misericordia de Porto Alegre, Porto Alegre

18618-686

UPECLIN - Unidade de Pesquisa Clínica da Faculdade de Medicina de Botucatu - FMB/UNESP, Botucatu

CEP 30150-221

Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte

05403-000

Clinical Research Center, Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo

34295 CEDEX 5

Center Hospitalier Universitaire de Montpellier, Montpellier

6500 HB

Radbound University Medical Center, Nijmegen

W12 0HS

Imperial College Healthcare NHS Trust, London

NE7 7DN

Freeman Hospital, Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Apellis Pharmaceuticals, Inc.

INDUSTRY

NCT04572854 - Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN | Biotech Hunter | Biotech Hunter